A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Changhoon Yoo, Sung-Bae Kim, Jin-Hee Ahn, Jeong Eun Kim, Kyung Hae Jung, Gyung-Yub Gong, Byung-Ho Son, Sei-Hyun Ahn, Seung Do Ahn, Hak-Hee Kim, Hee Jung Shin, Woo Kun Kim
Cancer Res Treat. 2015;47(3):406-415. Published online 2014 Nov 27 DOI: https://doi.org/10.4143/crt.2014.073
Citations to this article as recorded by 
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
Siao-Nge Hoon, Peter K H Lau, Alison M White, Max K Bulsara, Patricia D Banks, Andrew D Redfern
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
rApoptin induces apoptosis in human breast cancer cells via phosphorylation of Nur77 and Akt
Zhenhuan Hou, Jun Mao, Ying Lu, Lianhong Li
Biochemical and Biophysical Research Communications.2018; 498(1): 221. CrossRef
Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties
Mick Van de Wiel, Yanina Dockx, Tim Van den Wyngaert, Sigrid Stroobants, Wiebren A.A. Tjalma, Manon T. Huizing
European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 210: 144. CrossRef
Human serum albumin-mediated apoptin delivery suppresses breast cancer cell growth in vitro and in vivo
Fang Wu, Yizhi Liu, Jian Li, Lei Hou, Fuxi Lei, Shangke Huang, Lu Feng, Xinhan Zhao
Oncology Letters.2017; 13(2): 579. CrossRef
Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials
Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin, Xu-Yuan Li, Hemant Kumar Bid
PLOS ONE.2016; 11(10): e0164663. CrossRef